Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/120651
Title: Lung resistance-related protein as a predictor of clinical outcome in advanced testicular germ-cell tumours
Author: Zurita, A. J.
Diestra, J. E.
Condom i Mundó, Enric
García del Muro Solans, Xavier
Scheffer, G. L.
Scheper, R. J.
Pérez, J.
Germà Lluch, José Ramón
Izquierdo, M. A.
Keywords: Malalties del testicle
Cèl·lules germinals
Tumors
Expressió gènica
Proteïnes supressores de tumors
Resistència als medicaments
Testis diseases
Germ cells
Tumors
Gene expression
Tumor suppressor protein
Drug resistance
Issue Date: 24-Mar-2003
Publisher: Cancer Research UK
Abstract: This study was undertaken to investigate the expression and predictive value for outcome of multidrug resistance-associated (MDR) proteins P-glycoprotein (Pgp), MRP1, BCRP, and LRP, in advanced testicular germ-cell tumours (TGCT). Paraffin-embedded sections from 56 previously untreated patients with metastatic TGCT were immunostained for Pgp, MRP1, BCRP, and LRP. All patients received platinum-based chemotherapy after orchidectomy. Immunostaining was related to clinicopathological parameters, response to chemotherapy, and outcome. Strong and intermediate expressions of the different MDR-related proteins were: 27 and 41% (Pgp), 54 and 37% (MRP1), 86 and 7% (BCRP), and 14 and 29% (LRP). P-glycoprotein and MRP1 associated, respectively, to low AFP (P=0.026) and high LDH levels (P=0.014), whereas LRP expression associated with high β-hCG levels (P=0.003) and stage IV tumours (P=0.029). No correlation was found between Pgp, MRP1, and BCRP expression and response to chemotherapy and survival. In contrast, patients with LRP-positive tumours (strong or intermediate expression) had shorter progression-free (P=0.0006) and overall survival (P=0.0116) than LRP-negative patients, even after individual log-rank adjustments by statistically associated variables. Our data suggest that a positive LRP immunostaining at the time of diagnosis in metastatic TGCT is associated with an adverse clinical outcome.
Note: Reproducció del document publicat a: https://doi.org/10.1038/sj.bjc.6600803
It is part of: British Journal of Cancer, 2003, vol. 88, num. 6, p. 879-886
URI: http://hdl.handle.net/2445/120651
Related resource: https://doi.org/10.1038/sj.bjc.6600803
ISSN: 0007-0920
Appears in Collections:Articles publicats en revistes (Patologia i Terapèutica Experimental)
Articles publicats en revistes (Ciències Clíniques)

Files in This Item:
File Description SizeFormat 
524876.pdf197.12 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons